One thing that The NaDDir* didn’t address on last week’s bizarre conference call by everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), was the recruiting status of the much vaunted “CD12” study of loserlimab in severe-to-critical Covid-19 patients.
Recall that prestigious Ivy League university in Connecticut that was participating in the study (but never actually recruited a single patient?). Sure you do. Here’s the Clinicaltrials.gov record of study locations as of mid-August:
On August 31st, the company quietly deleted Yale from the trial location list (and it looks like Eisenhower Health in California dumped CYDY too).
And speaking of trial sites, remember that press release back on August 20th, where Cytodyn claimed that they received authorization to enroll UK patients, commencing immediately, into its ongoing Covid-19 trial?
Go back and review the list of trial sites as of August 31st, available here. Interesting that there are no UK sites listed. Not one. On the conference call last week, The NaDDir* did make some curious comments about UK trial enrollment:
“We received great news today. UK ethical committee approved CD12 study to be conducted in the UK. Now, the study can officially be initiated. Please also see our MHRA comments below”. They have recommended, CytoDyn to resubmit the CytoDyn CD12 COVID-19 study to the urgent public health, UPH scheme.”
Was the company lying about being approved to begin recruiting UK patients in the August 20th press release? It seems so. And exactly why did the company need to resubmit the study? Was it really because wink wink nudge nudge the UK health authorities love it so much? Or is it (much more likely given Cytodyn’s history), because the original filing was deficient in some way? Or maybe the MHRA (like the FDA with Cytodyn’s pathetic HIV BLA) just wanted a Double Dose of The NaDDir’s* sweet sweet regulatory filings?
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.
LoserLimab!! Really!!!! Any single statement here about science? And about the PR statements done by CYDY, you will know that very shortly. Well, your article shows what character you have, hope you dont have to depend on this drug!!
[Oh yes, “teh science“, you can read up on it here. – Editor]
LOL…you sound like a sour short who got burned…
[You need to read “When Prophecy Failed” – Editor]
Who is the author? I don’t see any names. How can this information be trusted? I hope you don’t get Covid-19 and die before you’re able to reveal yourself.
[Well, you could start by clicking on all of the provided links that verify everything in the post. You do know how hyperlinks work, right? – Editor]
I however is paying you to distort did not get there monies worth. That had to be the lamest bash I’ve seen. Congrats
[We normally don’t point out commenters information, but this particular user, from Van Nuys, CA, has been commenting under multiple aliases. Try harder. – Editor]
Any “news article” that has not one but two childish, name-calling examples in the OPENING PARAGRAPH is an article to be trusted… (where’s that eye-roll emoji when I need it??) What an embarrassing attempt to cast doubt on a drug that has been proven to work time and time again. I would say that you should be ashamed of yourself but after reading your so-called ‘article’, it would appear that you wouldn’t know shame if it walked up and bit you in the ass. I’m genuinely embarrassed for you.
[Weird that you keep reading and posting comments then. Of course you are commenting from Vancouver, WA, Cytoscam’s home town. – Editor]